Granules India, a Rs. 760 crore plus Hyderabad based pharma company, has posted impressive financial performance during the third quarter ended December 2013. The growth was across all manufacturing facilities including the formulation facility at Gagillapur which continued to scale-up production.  Its net profit has taken a quantum jump of 275 per cent to Rs. 21.80 crore from Rs. 5.80 crore in the corresponding period of last year. Its EBDITA also moved up by 140 per cent to Rs. 45.54 crore from Rs. 18.99 crore.. Its net sales also moved up sharply by 45.5 per cent to Rs. 284.05 crore from Rs. 195.22 crore.

After the announcement of strong financial performance for third quarter, Granules India scrip has touched to its yearly highest level at Rs. 228.20 today. It moved up by almost 7 per cent or Rs. 14.55 to Rs. 224 in the afternoon session.  Granules produces finished dosages, pharmaceutical formulation intermediates and APIs. Its global presence extends to over 300 customers in 60 countries.

For the first nine months ended December 2013, Granules' net sales increased by 39 per cent to Rs. 778.39 crore from Rs. 559.98 crore in the similar period of last year. Its net profit went up smartly by 156 per cent to Rs. 51.60 crore from Rs. 28.15 crore. EPS worked out to Rs. 25.57 as against Rs. 10.04 in the last period.

Krishna Prasad, managing director, said, “We have increased revenue and PAT in four quarters in a row which is why our revenue for the first nine months surpassed our FY13 revenue and more importantly, our PAT is 58 per cent higher than last year's total. Our standalone operations continue to strengthen and I believe our numbers reflect the potential of our business. While we are proud of our accomplishment, our primary focus continue to be improving manufacturing efficiency so we can deliver unparalleled value to our customers.”